Download CV
Download CV
DR. ROBERT W. HERRING, JR. is a native of Nashville. He attended John Overton High School where he was valedictorian and a National Merit Scholar in 1972. He was the 1972 Debate Champion of the Southeast Region of the National Forensic League as well as State Champion. A Phi Beta Kappa scholar, he received double majors in Biology and Chemistry at Birmingham-Southern College graduating summa cum laude. He was also President of the Alpha Tau Omega social fraternity. He received his Doctor of Medicine degree from the University of Tennessee where he was in the scholastic honors fraternity, Alpha Omega Alpha. He was also Vice-President of his medical school class. He did his Internal Medicine Residency at Wake Forest University and his Gastroenterology and Hepatology Fellowship at Johns Hopkins University in 1985. He is Board Certified in Internal Medicine, Gastroenterology, and Hepatology. Dr. Herring is a Fellow of the American College of Gastroenterology, and is a former Governor of the Tennessee Chapter. He chaired the Governmental Affairs Committee of the Tennessee Medical Association after serving for ten years. He served as President of the Young Physicians Section of the Tennessee Medical Association. Dr. Herring is a past president of the Tennessee Society for Gastroenterology and Endoscopy. He is also President of the Middle Tennessee Gastroenterology Independent Practice Association.
ARTICLES
Additional articles that Dr. Herring has authored and co-authored are listed below, please click on the article to review the abstract of that study
- All-oral combination of ledipasvir, vedroprevir,tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection
- PROPEL: A Randomized Trail of Mericitabine Plus Peginterferon Alpha-2a Therapy in Treatment-Naïve HCV Genotype ¼ Patients
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatement options
- Safety and Tolerance of Oral 5-ASA (Asacol) in the treatment of Ulcerative Colitis and Crohn’s Disease: Results of the US Multicenter Open-Label Study
- Balapiravir Plus Pegiterferon alfa-2a (40KD) and Ribavirin for the treatment of Chronic Hepatitis C Genotype 1: Randomized Double-Blind, Placebo-Controlled Phase 2 Study
- Racial differences in response rates to consensus interferon in HCV infected patient’s naïve to previous therapy
- Oral 5-ASA (Asacol) in the treatment of Mild to Moderate Ulcerative Colitis (UC): The Nashville Experience
- Effect of acute alcohol administration on erythrocyte aldehyde dehydrogenase activity in man
For more information regarding Dr. Herring’s private non research practice visit www.herringmd.com
You will need the Adobe Reader to view and print these documents.
